Contrast Agents

Contrast Agents

Intravenous contrast material for CT appears to be safe for most patients, including those with a predisposition to nephrotoxicity.

The FDA has given Bayer’s Gadavist approval for use with MRI of the breast to evaluate malignant breast disease.

Radiologists tend to get a bad rap, but when it comes to imaging studies, we know best.


The latest dual source CT includes features that provide low dose imaging for patients with renal insufficiency, difficulty holding their breath and more.

Didactic module helps prepare clinicians for managing adverse reactions to media, more training still needed.

Pacemaker in x ray

Study provides no additional evidence supporting 2008 FDA advisory that warned CT scans potentially interfere with CRM devices.

Patients who underwent CT with or without contrast had similar rates of acute kidney injury, showing contrast use isn’t associated with nephropathy.


Subscribe to Contrast Agents on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.